Related Experiment Video

Updated: Jul 13, 2026

Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine

K Raj1, A John, A Ho

  • 1King's College London, Department of Haematological Medicine, Denmark Hill Campus, London, UK.

Leukemia
|July 6, 2007
PubMed

Insights

5-Azacytidine effectively treats myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Cytotoxicity, not gene demethylation, appears to drive patient responses to this DNA methyl transferase inhibitor.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • 5-Azacytidine is a DNA methyl transferase inhibitor used for myelodysplastic syndromes (MDS).
  • The precise mechanism of 5-Azacytidine's efficacy, whether via gene demethylation or cytotoxicity, remains unclear.
  • Understanding the response mechanism is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To investigate the mechanism of action of 5-Azacytidine in patients with MDS and acute myeloid leukemia (AML).
  • To determine whether responses are mediated by gene demethylation or direct cytotoxicity.
  • To identify predictive markers for treatment response.

Main Methods:

  • 34 patients with MDS or AML were treated with 5-Azacytidine.
  • Bone marrow (BM) blast counts, complete remissions (CR), and hematological improvement (HI) were assessed.
  • Bisulphite genomic sequencing (BGS) analyzed CDKN2B (p15(INK4b)) promoter methylation.
  • Cell death markers, including BM cellularity and apoptosis, were evaluated.

Main Results:

  • 7 patients (21%) achieved CR, and 6 achieved HI.
  • Lower baseline CDKN2B methylation was observed in responders (9.8% vs. 16.2%).
  • At 75 mg/m², reduced BM cellularity and increased apoptosis correlated with response, not CDKN2B demethylation.
  • Patients with >24% methylation showed no response.

Conclusions:

  • Cytotoxicity, characterized by reduced BM cellularity and increased apoptosis, appears to be the primary mechanism of 5-Azacytidine response at 75 mg/m².
  • CDKN2B demethylation does not correlate with treatment response.
  • Patients with high baseline methylation (>24%) may require alternative dosing or combination therapies.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...